SCHEMBL2198685

SCHEMBL2198685

Cc1c(C(=O)O)n[nH]c1-c1cccc(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.43
HAO2 Q9NYQ3 1/20 0.43
GPR55 Q9Y2T6 1/20 0.42
NPC1 O15118 5/20 0.41
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 2/20 0.40
APOBEC3G Q9HC16 2/20 0.40
HCAR2 Q8TDS4 2/20 0.40
ALOX15 P16050 2/20 0.40
CDC7 O00311 1/20 0.40
HSP90AA1 P07900 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27658275 0.85 HAO2 (0.54) HAO2HCAR2KDM4EPIN1
SCHEMBL570062 0.83 PIN1 (0.47) HAO2NPC1RAB9AALDH1A1KMT2A
SCHEMBL569461 0.83 PIN1 (0.56) HAO2HCAR2PIN1
SCHEMBL2197641 0.83 ALOX5 (0.51) NPC1RAB9AALDH1A1MAPTHSD17B10
SCHEMBL14152277 0.80 PIN1 (0.58) HAO2CDC7PIN1
SCHEMBL16883789 0.75 ALK (0.48) IKBKBALDH1A1HTTHCAR2KDM4E
SCHEMBL27916610 0.75 ALDH1A1 (0.41) IKBKBGPR55NPC1RAB9AALDH1A1
SCHEMBL27935266 0.74 ALDH1A1 (0.49) IKBKBGPR55NPC1RAB9AALDH1A1
SCHEMBL4964605 0.73 HAO2 (0.53) HAO2MAPTHCAR2RPA1
SCHEMBL16197762 0.73 ALPL (0.46) IKBKBNPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 IKBKB 2960/4885HAO2 4387/4885GPR55 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.